Viveve Medical, Inc.
VIVE · OTC
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Revenue | $6 | $5 | $7 | $19 |
| % Growth | 17.3% | -16.6% | -64.5% | – |
| Cost of Goods Sold | $6 | $5 | $6 | $11 |
| Gross Profit | $1 | $0 | $1 | $7 |
| % Margin | 9.6% | 5.4% | 15.5% | 39.5% |
| R&D Expenses | $10 | $5 | $9 | $14 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $13 | $14 | $22 | $39 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $22 | $19 | $31 | $52 |
| Operating Income | -$22 | -$18 | -$30 | -$45 |
| % Margin | -335.4% | -337.6% | -455.9% | -242.8% |
| Other Income/Exp. Net | -$0 | -$3 | -$11 | -$4 |
| Pre-Tax Income | -$22 | -$22 | -$42 | -$49 |
| Tax Expense | $0 | $0 | $5 | -$0 |
| Net Income | -$22 | -$22 | -$43 | -$49 |
| % Margin | -342.8% | -400% | -647.6% | -265.6% |
| EPS | -2.65 | -16.56 | -121.91 | -1,583.5 |
| % Growth | 84% | 86.4% | 92.3% | – |
| EPS Diluted | -2.65 | -16.56 | -121.91 | -1,583.5 |
| Weighted Avg Shares Out | 10 | 2 | 0 | 0 |
| Weighted Avg Shares Out Dil | 10 | 2 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $1 | $4 | $4 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$20 | -$19 | -$31 | -$44 |
| % Margin | -305.5% | -352.7% | -467.2% | -238.5% |